Displaying 841 - 860 of 4776
FTC Takes Action to Ban Payment Processor From Debt Relief Processing
FTC Sends Full Refunds Totaling Over $2 Million to Consumers who Lost Money Through Deceptive Direct Mail Publications Scheme
Agora Financial LLC
The FTC sued a publisher called Agora Financial, LLC, alleging that it tricks seniors into buying books, newsletters, and other publications that falsely promise a cure for type 2 diabetes or promote a phony plan to help them cash in on a government-affiliated check program. According to the FTC’s complaint, Agora Financial and some of its affiliates target publications, including The Doctor’s Guide to Reversing Diabetes in 28 Days (The Doctor’s Guide), primarily at older consumers nationwide, as well as pitching them on a fake scheme to cash in on Congress’ Secret $1.17 Trillion Giveaway. The FTC announced a proposed order settling the allegations against all defendants in February 2021.
FTC Sues Utah-based Company for Falsely Claiming Its Nasal Sprays Can Prevent and Treat COVID-19
FTC to Ramp up Enforcement against Illegal Dark Patterns that Trick or Trap Consumers into Subscriptions
FTC and DOJ to Hold Virtual Public Workshop Exploring Competition in Labor Markets
FTC Strengthens Security Safeguards for Consumer Financial Information Following Widespread Data Breaches
Federal Trade Commission Cigarette Report for 2020 and Smokeless Tobacco Report for 2020
FTC Report Finds Annual Cigarette Sales Increased for the First Time in 20 Years
FTC Puts Businesses on Notice that False Money-Making Claims Could Lead to Big Penalties
FTC Staff Report Finds Many Internet Service Providers Collect Troves of Personal Data, Users Have Few Options to Restrict Use
Funder and Servicer of Online Trading Academy Payment Plans Will Forgive Debt in Settlement with FTC
FTC Sends Refunds to Consumers Who Bought Deceptively Marketed Supplements to Treat Pain and Age-related Health Conditions
Nordic Clinical, Inc. and Encore Plus Solutions, Inc.
In April 2020, the marketers of three supplements called Neurocet, Regenify, and Resetigen-D settled FTC charges that they deceptively promoted their products to older Americans using false claims that their products could stop pain and treat age-related ailments. The proposed order bars the defendants—five related companies and their principals from making any claims about the health benefits of their products unless they are true and supported by scientific evidence. In October 2021, the FTC announced it was returning $1.1 million to consumer who bought the defendants’ products.
FTC Issues Annual Report to Congress on Protecting Older Adults
New FTC Staff Report Outlines Impact of Fraud on Communities of Color
Displaying 841 - 860 of 4776